Humacyte HUMA
NASDAQ HUMA
$0.41 +0.01 (+1.28%)
At close: Oct 21, 2026 · 4:00 PM EDT

Humacyte (HUMA) Net Margin (2020 - 2026)

Updated

Humacyte (HUMA) reported Net Margin of -9064.53% for Q2 2026, up 3446.43 percentage points from -12510.96% a year earlier but down 5505.14 percentage points from the prior quarter.

Analysis

Humacyte (HUMA) Net Margin (2020 - 2026) Analysis & Trends

Over the twelve months ended Jun 30, 2026, Humacyte's Net Margin came in at -4560.82%, up 2610.45 percentage points year-over-year; for FY2025, it was -2003.58%.

  • Five-year quarterly Net Margin spans a low of -13096.68% in Q3 2021 and a high of 7570.41% in Q1 2025.
  • Per Business Quant data, the three quarters before Q2 2026 came in at -3559.39% (Q1 2026), -5311.35% (Q4 2025) and -2325.37% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 30.88%
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 21.86%
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 21.27%
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn -8.04%
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 22.65%
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 16.30%
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 23.62%
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -134.51%
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn -1.65%
10 Humacyte 97.33 Mn -101.11 Mn -825,000.00 -9,064.53%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -9,064.53%
Mar 31, 2026 -3,559.39%
Dec 31, 2025 -5,311.35%
Sep 30, 2025 -2,325.37%
Jun 30, 2025 -12,510.96%
Mar 31, 2025 7,570.41%
Sep 30, 2021 -13,096.68%
Sep 30, 2020 -4.48%
API Access

Humacyte Net Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-margin&ticker=HUMA&period=max&api_key=YOUR_API_KEY